(NASDAQ: PHAT) Phathom Pharmaceuticals's forecast annual revenue growth rate of 651.65% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Phathom Pharmaceuticals's revenue in 2024 is $682,000.On average, 2 Wall Street analysts forecast PHAT's revenue for 2024 to be $2,615,107,137, with the lowest PHAT revenue forecast at $2,570,079,576, and the highest PHAT revenue forecast at $2,660,134,697. On average, 2 Wall Street analysts forecast PHAT's revenue for 2025 to be $8,107,592,329, with the lowest PHAT revenue forecast at $7,784,504,965, and the highest PHAT revenue forecast at $8,430,679,694.
In 2026, PHAT is forecast to generate $17,603,436,972 in revenue, with the lowest revenue forecast at $15,614,622,264 and the highest revenue forecast at $19,592,251,679.